Empagliflozin for heart failure in children
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests if empagliflozin, a diabetes medicine that also helps the heart, can improve symptoms in children with heart failure. It may help kids with severe symptoms or high levels of a heart stress marker called BNP.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 month and 18 years old.
- You must have heart failure diagnosed by tests showing the heart doesn't pump or fill well.
- You must have moderate to severe symptoms (Ross class III or IV) or a BNP level over 300 pg/mL.
- You cannot have severe kidney disease (eGFR below 60).
- You cannot have a kidney infection or allergy to empagliflozin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called sotagliflozin for people who have both type 1 diabetes and heart failure symptoms. The goal is to see if it can improve how you feel and manage your heart and diabetes.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This trial tests if a diabetes medicine called empagliflozin can help people with Fontan circulatory failure feel better and do more of their daily activities.
This trial studies whether a medicine called empagliflozin, currently used for diabetes, can help improve heart function in children with Duchenne muscular dystrophy who also have heart muscle weakness. The medicine is given as a pill and aims to slow down the heart damage so children can feel better for longer.
This trial tests whether a diabetes medicine called empagliflozin can improve the quality of life for people who have both chronic heart failure with a weak heart pump and type 2 diabetes. It compares the effects of adding empagliflozin to your current treatments.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.